Recombinant hirudin as an anticoagulant during cardiac operations: Experiments in a pig model

European Journal of Cardio-thoracic Surgery

Volumn 11, Issue 4, 1997, Pages 739-745

  Riess, Friedrich Christian ^a,c   Pötzsch, Bernd ^a   Behr, Ines ^a   Jäger, Kirsten ^a   Rössing, Ragnhild ^b   Bleese, Niels ^a,c   Schaper, Wolfgang ^a   Müller Berghaus, Gert ^a  

^a KERCKHOFF HEART CENTER   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c ALBERTINEN KRANKENHAUS   (Germany)

Author keywords

Anticoagulation; Cardiac surgery; Cardiopulmonary bypass; Extracorporeal circulation; Recombinant hirudin

Indexed keywords

APROTININ; HEPARIN; LEPIRUDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; FEMALE; HEART DISEASE; HEART SURGERY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SWINE;

ANIMALS; ANTICOAGULANTS; BLEEDING TIME; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXTRACORPOREAL CIRCULATION; HEPARIN; HIRUDINS; OXYGENATORS, MEMBRANE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; SWINE;

EID: 0342506847     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(96)01070-6     Document Type: Article

References (34)

1. Arthur CK, Isbister JP, Aspery EM. The heparin induced thrombosis-thrombocytopenia syndrome (HITTS): a review. Pathology 1985;17:82-86.
2. Bichler J, Fritz H. Hirudin, a new therapeutic tool? Ann Hematol 1991;63:67-76.
3. Bucha E, Markwardt F, Nowak G. Hirudin in haemodialysis. Thromb Res 1990;60:445-455.
4. Chang JY. White clot syndrome associated with heparin-induced thrombocytopenia: a review of 23 cases. Heart Lung 1987;16:403-407.
5. Conrad KA. Clinical pharmacology and drug safety: lessons from hirudin. Clin Pharmacol Ther 1995;58:123-126.
6. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years experience in 1784 patients. J Cardiothorac Vasc Anesth 1992;6:324-327.
7. Fareed D, Pifarre R, Walenga JM, Fareed J. Effect of recombinant hirudin and heparin on human platelet aggregation. Fed Proc 1989;3:A308.
8. Folkers PJM, Clore GM, Driscoll PC, Dodt J, Kohler S, Gronenborn AM. Solution structure of recombinant hirudin and the Lys-47-Glumutant: a nuclear magnetic resonance and hybrid distance geometry-dynamical simulated annealing study. Biochemistry 1989;28:2601-2617.
9. Glusa E, Markwardt F. Platelet functions in recombinant hirudin-anticoagulated blood. Haemostasis 1990;20:112-118.
10. Green D, Sanders J, Eiken M, Wong CA, Frederiksen J, Joob A, Palmer A, Trowbridge A, Woodruff B, Moerch M, Tabanera R, Edsberg B. Recombinant aprotinin in coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1995;110:963-970.
11. Hope AF, Heyns AduP, Lötter MG, van Reenen OR, de Kock F, Badenhorst PN, Pieters H, Kotze H, Meyer JM, Minnaar PC. Kinetics and sites of sequestration of indium 111-labeled human platelets during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981;81:880-886.
12. Horneffer PJ, Gott VL, Gardner TJ. Swine as a cardiac surgical model. In: Umbleson ME, editor. Swine in biomedical research, Vol. 1. New York: Plenum, 1986:321-325.
13. Köstering H, Mast WP, Kaethner T, Nebendahl K, Holtz WH. Blood coagulation studies in domestic pigs (Hanover breed) and minipigs (Göttingen breed). Lab Animals 1983;17:346-349.
14. Lam JYT, Chesebro JH, Steele PM, Heras M, Webster MWI, Badimon L, Fuster V. Antithrombotic therapy for deep arterial injury by angioplasty. Circulation 1991;84:814-820.
15. Levy JH. Anaphylactic reactions in anesthesia and intensive care, second ed. Boston: Butterworth-Heinemann, 1992.
16. Markwardt F, Hoffmann A, Stürzenbecher J. Influence of thrombin inhibitors on the thrombin-induced activation of human blood platelets. Haemostasis 1983;13:227-233.
17. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994;74:1-23.
18. Nowak G, Markwardt F, Fink E. Pharmacokinetic studies with recombinant hirudin in dogs. Folia Haematol 1988;115:70-74.
19. Pötzsch B, Grulich-Henn J, Rössing R, Wille D, Müller-Berghaus G. Identification of endothelial and mesothelial cells in human omental tissue and in mentum-derived cells by specific cell markers. Lab Invest 1990;63:841-852.
20. Pötzsch B, Iversen S, Riess FC, Tzanova N, Seelig C, Nowak G, and Müller-Berghaus G. Recombinant hirudin as an anticoagulant in open-heart surgery: a case report. Ann Hematol 1994;68(Suppl II):A53.
21. Riess FC, Löwer C, Seelig C, Bleese N, Kormann J, Müller-Berghaus G, Pötzsch B. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995;110:265-267.
22. Riess FC, Pötzsch B, Bader R, Bleese N, Greinacher A, Löwer C, Madlener K and Müller-Berghaus G. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open-heart surgery. Eur J Cardio-Thorac Surg 1996;10:386-388.
23. Riess FC, Pötzsch B, Jäger K, Bleese N, Müller-Berghaus G. Elimination of recombinant hirudin by hemofiltration in the pig model. Isr J Med Sci 1996;32:955 (abstract).
24. Salzman EW. Blood platelets and extracorporeal circulation transfusion. Transfusion 1963;3:274-277.
25. Schwartz RS, Murphy IG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990;82:2190-2200.
26. Singer RL, Mannion JD, Bauer TL, Armenti FR, Edie RN. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest 1993;104: 1436-1440.
27. Spannagl M, Bichler J, Birg A, Lill H, Schramm W. Development of a chromogenic substrate assay for the determination of hirudin in plasma. Blood Coag Fibrinol 1991;2:121-127.
28. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochem 1986;25:4622-4628.
29. Tonz M, Mihaljevic T, von Segesser LK, Schmid ER, Joller-Jemelka HI, Turina MI. Normothermia versus hypothermia during cardiopulmonary bypass: a randomized controlled trial. Ann Thorac Surg 1995;59:137-143.
30. Umlas J, Taff RH, Garvin G, Sevierk R. Anticoagulant monitoring and neutralization during open heart surgery - a rapid method for measuring heparin and calculating safe reduced protamine doses. Analg 1993;62:1095-1099.
31. Walenga JM, Pifarre R, Hoppensteadt DA, Fareed J. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations. Semin Thromb Hemostas 1989;15:316-333.
32. Walenga JM, Bakhos M, Messmore HL, Fareed J, Pifarre R. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg 1991;51:271-277.
33. Walenga JM, Koza MJ, Park SJ, Terrell MR, Pifarre R. Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model. Ann Thorac Surg 1994;58:1685-1689.
34. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680-1697.